[{"id":"64497f54-38a5-401a-93f0-04cf9d26aa99","acronym":"ACCELERATE","url":"https://clinicaltrials.gov/study/NCT07013565","created_at":"2025-06-14T14:00:13.949Z","updated_at":"2025-06-14T14:00:13.949Z","phase":"Phase 2","brief_title":"Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL","source_id_and_acronym":"NCT07013565 - ACCELERATE","lead_sponsor":"New York Medical College","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • vinblastine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-06-10"},{"id":"bd95cf3a-a05b-4e87-b03d-357c3daa7c72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628767","created_at":"2021-01-29T07:21:36.268Z","updated_at":"2025-02-25T12:37:42.651Z","phase":"Phase 2/3","brief_title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","source_id_and_acronym":"NCT04628767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • liposomal gemcitabine (FF-10832) • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"638d5845-a2b6-4c6b-b8df-41704f0f7049","acronym":"MIRV","url":"https://clinicaltrials.gov/study/NCT06666348","created_at":"2025-02-25T15:37:40.797Z","updated_at":"2025-02-25T15:37:40.797Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK","source_id_and_acronym":"NCT06666348 - MIRV","lead_sponsor":"C17 Council","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib) • vinblastine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 04/01/2030","primary_completion_date":" 04/01/2030","study_txt":" Completion: 04/01/2035","study_completion_date":" 04/01/2035","last_update_posted":"2025-02-11"},{"id":"3a5c5d6a-237c-4943-9f23-41234e0aa377","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755804","created_at":"2021-01-18T18:27:48.805Z","updated_at":"2025-02-25T16:37:17.115Z","phase":"Phase 2","brief_title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","source_id_and_acronym":"NCT03755804","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-07"},{"id":"5f8b072a-82e7-4058-ac66-89f1f2f42c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576117","created_at":"2021-01-18T21:50:45.604Z","updated_at":"2025-02-25T16:32:16.258Z","phase":"Phase 3","brief_title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","source_id_and_acronym":"NCT04576117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1 • NF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E","tags":["BRAF • IDH1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"84dc5381-b2bd-414d-95d6-7e4b13384698","acronym":"","url":"https://clinicaltrials.gov/study/NCT01771107","created_at":"2021-01-18T07:48:13.309Z","updated_at":"2024-07-02T16:35:02.686Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma","source_id_and_acronym":"NCT01771107","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/07/2013","start_date":" 03/07/2013","primary_txt":" Primary completion: 10/15/2021","primary_completion_date":" 10/15/2021","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-17"},{"id":"81eb8371-f87d-49c5-88e5-0d0d26e56e1d","acronym":"VICTORY","url":"https://clinicaltrials.gov/study/NCT06381570","created_at":"2024-04-24T17:31:03.430Z","updated_at":"2024-07-02T16:35:07.877Z","phase":"Phase 1","brief_title":"Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas","source_id_and_acronym":"NCT06381570 - VICTORY","lead_sponsor":"Daniel Morgenstern","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 03/21/2024","start_date":" 03/21/2024","primary_txt":" Primary completion: 03/21/2026","primary_completion_date":" 03/21/2026","study_txt":" Completion: 03/21/2029","study_completion_date":" 03/21/2029","last_update_posted":"2024-04-24"},{"id":"26dcc42b-ad10-4971-bd48-90b2e6447b5b","acronym":"PLGG - MEKTRIC","url":"https://clinicaltrials.gov/study/NCT05180825","created_at":"2022-01-06T22:53:32.817Z","updated_at":"2024-07-02T16:35:18.783Z","phase":"Phase 2","brief_title":"Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy","source_id_and_acronym":"NCT05180825 - PLGG - MEKTRIC","lead_sponsor":"University Hospital, Strasbourg, France","biomarkers":" BRAF • IDH1 • NF1 • MYBL1","pipe":" | ","alterations":" IDH1 mutation","tags":["BRAF • IDH1 • NF1 • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • vinblastine"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 11/01/2031","primary_completion_date":" 11/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-02-19"},{"id":"93a88c34-d0f2-492b-a36d-f9ea207da396","acronym":"C25004","url":"https://clinicaltrials.gov/study/NCT02979522","created_at":"2021-01-18T14:39:24.684Z","updated_at":"2024-07-02T16:35:18.840Z","phase":"Phase 1/2","brief_title":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","source_id_and_acronym":"NCT02979522 - C25004","lead_sponsor":"Takeda","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 05/05/2020","primary_completion_date":" 05/05/2020","study_txt":" Completion: 09/24/2029","study_completion_date":" 09/24/2029","last_update_posted":"2024-02-19"},{"id":"d6f097ba-9519-4376-8dfc-112499960700","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840409","created_at":"2021-01-18T13:56:34.086Z","updated_at":"2024-07-02T16:35:21.598Z","phase":"Phase 2","brief_title":"Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)","source_id_and_acronym":"NCT02840409","lead_sponsor":"The Hospital for Sick Children","biomarkers":" BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1","pipe":" | ","alterations":" BRAF mutation • FGFR1 fusion","tags":["BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • FGFR1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-01-31"},{"id":"b53b591c-7a34-44d3-8a4e-88612967f74d","acronym":"AMC-085","url":"https://clinicaltrials.gov/study/NCT02298257","created_at":"2021-01-18T10:50:16.201Z","updated_at":"2024-07-02T16:35:35.674Z","phase":"Phase 2","brief_title":"A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma","source_id_and_acronym":"NCT02298257 - AMC-085","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 08/08/2022","study_completion_date":" 08/08/2022","last_update_posted":"2023-09-26"},{"id":"4f76cd83-e646-4932-a2d7-78e27c5572aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01868451","created_at":"2021-01-18T08:21:39.824Z","updated_at":"2024-07-02T16:35:43.603Z","phase":"","brief_title":"Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma","source_id_and_acronym":"NCT01868451","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-07-07"},{"id":"d5f97284-f241-4922-aff7-91252d0fa774","acronym":"","url":"https://clinicaltrials.gov/study/NCT01700946","created_at":"2021-01-18T07:23:42.396Z","updated_at":"2024-07-02T16:36:03.318Z","phase":"Phase 2","brief_title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","source_id_and_acronym":"NCT01700946","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • clofarabine • mitoxantrone • Oncaspar liquid (pegaspargase) • Vumon (teniposide) • mercaptopurine • vinblastine • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/15/2013","start_date":" 04/15/2013","primary_txt":" Primary completion: 07/24/2021","primary_completion_date":" 07/24/2021","study_txt":" Completion: 07/24/2021","study_completion_date":" 07/24/2021","last_update_posted":"2022-09-28"},{"id":"4b87c7c7-3bac-4f3c-931b-f9da998486ab","acronym":"BREACH","url":"https://clinicaltrials.gov/study/NCT02292979","created_at":"2021-01-18T10:48:37.178Z","updated_at":"2025-02-25T14:57:07.731Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.","source_id_and_acronym":"NCT02292979 - BREACH","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/02/2022","study_completion_date":" 06/02/2022","last_update_posted":"2022-08-19"},{"id":"712abef4-ee9f-449b-a706-9e273acea522","acronym":"","url":"https://clinicaltrials.gov/study/NCT00822120","created_at":"2021-01-18T03:07:31.140Z","updated_at":"2024-07-02T16:36:05.303Z","phase":"Phase 2","brief_title":"S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","source_id_and_acronym":"NCT00822120","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 371","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 04/30/2016","primary_completion_date":" 04/30/2016","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-08-18"},{"id":"b3e877a9-e318-445a-8349-2f2320be3756","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006455","created_at":"2021-01-17T23:53:50.880Z","updated_at":"2024-07-02T16:36:09.654Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)","source_id_and_acronym":"NCT00006455","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" ALK • NPM1 • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive","tags":["ALK • NPM1 • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • leucovorin calcium • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 885","initiation":"Initiation: 11/26/1999","start_date":" 11/26/1999","primary_txt":" Primary completion: 01/12/2009","primary_completion_date":" 01/12/2009","study_txt":" Completion: 09/03/2020","study_completion_date":" 09/03/2020","last_update_posted":"2022-05-31"},{"id":"53b9e1d8-7073-4fe0-85c6-56ed79f63077","acronym":"VINILO","url":"https://clinicaltrials.gov/study/NCT01884922","created_at":"2021-01-18T08:27:36.995Z","updated_at":"2024-07-02T16:36:09.735Z","phase":"Phase 1","brief_title":"Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults","source_id_and_acronym":"NCT01884922 - VINILO","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 05/29/2013","start_date":" 05/29/2013","primary_txt":" Primary completion: 09/02/2015","primary_completion_date":" 09/02/2015","study_txt":" Completion: 04/28/2016","study_completion_date":" 04/28/2016","last_update_posted":"2022-05-27"},{"id":"344a185c-4d14-4622-97e3-9f7082b8a174","acronym":"","url":"https://clinicaltrials.gov/study/NCT01132807","created_at":"2021-01-29T07:00:47.583Z","updated_at":"2024-07-02T16:36:29.143Z","phase":"Phase 2","brief_title":"Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","source_id_and_acronym":"NCT01132807","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 164","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2021-06-14"},{"id":"051f94e0-5dd8-4146-b3a3-a359a71f126b","acronym":"GETUG-AFU19","url":"https://clinicaltrials.gov/study/NCT02818725","created_at":"2021-01-18T13:49:22.558Z","updated_at":"2024-07-02T16:36:33.574Z","phase":"Phase 3","brief_title":"I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations","source_id_and_acronym":"NCT02818725 - GETUG-AFU19","lead_sponsor":"UNICANCER","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Vectibix (panitumumab) • doxorubicin hydrochloride • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 133","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2021-03-09"},{"id":"a5402968-68ab-4b67-9404-aa713ed1bfce","acronym":"(Optimist)","url":"https://clinicaltrials.gov/study/NCT03527628","created_at":"2021-01-18T17:23:16.028Z","updated_at":"2024-07-02T16:36:53.589Z","phase":"Phase 2","brief_title":"OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy","source_id_and_acronym":"NCT03527628 - (Optimist)","lead_sponsor":"King Abdullah International Medical Research Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 220","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/15/2022","study_completion_date":" 01/15/2022","last_update_posted":"2019-11-18"},{"id":"672de815-317e-4e2d-8372-7ac7a189d31d","acronym":"RCTACSCNSCLC","url":"https://clinicaltrials.gov/study/NCT03656393","created_at":"2021-01-18T17:56:48.327Z","updated_at":"2024-07-02T16:37:07.261Z","phase":"Phase 3","brief_title":"To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma","source_id_and_acronym":"NCT03656393 - RCTACSCNSCLC","lead_sponsor":"Shenzhen People's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gefitinib • vinorelbine tartrate • vinblastine"],"overall_status":"Unknown status","enrollment":" Enrollment 48","initiation":"Initiation: 08/31/2018","start_date":" 08/31/2018","primary_txt":" Primary completion: 07/31/2020","primary_completion_date":" 07/31/2020","study_txt":" Completion: 09/30/2020","study_completion_date":" 09/30/2020","last_update_posted":"2018-09-04"},{"id":"e67b8707-33b0-44fc-a15c-b9d6d41d0620","acronym":"","url":"https://clinicaltrials.gov/study/NCT00369681","created_at":"2021-01-18T01:17:02.212Z","updated_at":"2024-07-02T16:37:07.492Z","phase":"Phase 2","brief_title":"Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma","source_id_and_acronym":"NCT00369681","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • dacarbazine • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2018-08-27"},{"id":"de1fb083-4bde-4673-b7e4-8d04755d7430","acronym":"","url":"https://clinicaltrials.gov/study/NCT00030264","created_at":"2021-01-18T00:00:14.468Z","updated_at":"2024-07-02T16:37:08.149Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas","source_id_and_acronym":"NCT00030264","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 02/01/2001","start_date":" 02/01/2001","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2018-08-08"}]